Investment Analysts’ Weekly Ratings Updates for The Advisory Board Company (ABCO)

A number of firms have modified their ratings and price targets on shares of The Advisory Board Company (NASDAQ: ABCO) recently:

  • 2/9/2017 – The Advisory Board Company had its price target raised by analysts at Canaccord Genuity from $36.00 to $56.00. They now have a “buy” rating on the stock.
  • 2/6/2017 – The Advisory Board Company was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides its best practices research and analysis through discrete annual programs to a membership of more than 2,000 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program provides members with best practices research reports, executive education and other supporting research services. “
  • 2/6/2017 – The Advisory Board Company had its “hold” rating reaffirmed by analysts at Robert W. Baird.
  • 1/31/2017 – The Advisory Board Company had its price target raised by analysts at Stifel Nicolaus from $38.00 to $47.00. They now have a “hold” rating on the stock.
  • 1/13/2017 – The Advisory Board Company was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $42.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/13/2017 – The Advisory Board Company had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $36.00 price target on the stock.
  • 1/5/2017 – The Advisory Board Company had its price target lowered by analysts at Canaccord Genuity from $45.00 to $36.00. They now have a “buy” rating on the stock.
  • 1/4/2017 – The Advisory Board Company had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
  • 1/3/2017 – The Advisory Board Company was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides its best practices research and analysis through discrete annual programs to a membership of more than 2,000 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program provides members with best practices research reports, executive education and other supporting research services. “

The Advisory Board Company (NASDAQ:ABCO) traded up 0.85% on Tuesday, hitting $47.40. 854,876 shares of the company were exchanged. The company’s market capitalization is $1.90 billion. The firm’s 50 day moving average is $41.18 and its 200 day moving average is $39.90. The Advisory Board Company has a 52 week low of $18.87 and a 52 week high of $51.22.

In other The Advisory Board Company news, insider Cormac F. Miller sold 750 shares of the business’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $40.53, for a total value of $30,397.50. Following the transaction, the insider now directly owns 18,237 shares of the company’s stock, valued at approximately $739,145.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Hoose Mary Van sold 2,000 shares of the business’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $36.98, for a total transaction of $73,960.00. Following the completion of the transaction, the insider now directly owns 37,386 shares in the company, valued at $1,382,534.28. The disclosure for this sale can be found here. Insiders have sold a total of 32,884 shares of company stock valued at $1,262,106 in the last 90 days. Insiders own 2.90% of the company’s stock.

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

5 Day Chart for NASDAQ:ABCO

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/investment-analysts-weekly-ratings-updates-for-the-advisory-board-company-abco/1660790.html

Receive News & Ratings for The Advisory Board Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Company and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *